Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic [Seeking Alpha]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Seeking Alpha
RXRX's lead asset, REC-4881 for FAP, showed promising early efficacy but faces significant clinical and regulatory hurdles before approval. Despite high-profile partnerships and technological ambition, RXRX's cash burn remains substantial, with funding expected to last only into 2028. I downgrade RXRX stock to Hold, citing limited near-term catalysts, high risk, and an unproven business model in AI-driven drug discovery. Paper Boat Creative/DigitalVision via Getty Images Investment Overview Recursion Pharmaceuticals, Inc. ( RXRX ), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/ 10-K filing reported its earnings
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead [Seeking Alpha]Seeking Alpha
- Recursion's REC-4881 Milestone And Cash Runway Shift Risk Reward Profile [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RXRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Recursion Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/3/26 - Form 144
- 2/25/26 - Form S-8
- 2/25/26 - Form 424B5
- RXRX's page on the SEC website